Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopes, A.
Right arrow Articles by Bydlowski, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lopes, A.
Right arrow Articles by Bydlowski, S.

Chest, Vol 104, 1455-1460, Copyright © 1993 by American College of Chest Physicians

ARTICLES

Abnormal multimeric and oligomeric composition is associated with enhanced endothelial expression of von Willebrand factor in pulmonary hypertension

AA Lopes, NY Maeda, VD Aiello, M Ebaid and SP Bydlowski
Heart Institute, University of Sao Paulo, Brazil.

Abnormalities in endothelial von Willebrand factor (vWF) structure have been reported in pulmonary hypertension. These include loss of high molecular weight plasma multimers, resulting in decreased biologic activity. If endothelial processing of vWF is altered in this disorder, abnormalities in oligomeric composition may also be expected. We examined this possibility in ten adult patients with primary pulmonary hypertension. Enhanced endothelial vWF expression in these patients was indicated by increased plasma levels of vWF antigen (vWF:Ag) (214 +/- 91 vs 99 +/- 51 percent activity in controls, p < 0.001) and intense immunoperoxidase stain of pulmonary arterial endothelium for vWF (autopsy, 1 patient). Plasma from these patients also had a decreased capacity of inducing platelet aggregation in the presence of ristocetin, relative to vWF:Ag levels (57 +/- 20 percent activity). In addition to mild loss of the largest multimers, changes in oligomeric composition of plasma vWF were observed in most patients using both agarose and polyacrylamide gel electrophoresis. These included decreased concentration of dimeric (470 kDa) vWF in most patients, variable concentration of the 860-kDa fraction, and a relative decrease in subunit (223 kDa) density in subjects with elevated vWF:Ag. These findings provide additional information on the mechanisms responsible for endothelial production of dysfunctional vWF in patients with pulmonary hypertension.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
S. R. Johnson, S. Mehta, and J. T. Granton
Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review.
Eur. Respir. J., November 1, 2006; 28(5): 999 - 1004.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. M. Kawut, E. M. Horn, K. K. Berekashvili, A. C. Widlitz, E. B. Rosenzweig, and R. J. Barst
von Willebrand Factor Independently Predicts Long-term Survival in Patients With Pulmonary Arterial Hypertension
Chest, October 1, 2005; 128(4): 2355 - 2362.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. Friedman, J. G. Mears, and R. J. Barst
Continuous Infusion of Prostacyclin Normalizes Plasma Markers of Endothelial Cell Injury and Platelet Aggregation in Primary Pulmonary Hypertension
Circulation, November 4, 1997; 96(9): 2782 - 2784.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American College of Chest Physicians.